173 related articles for article (PubMed ID: 9649261)
1. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia.
Pannek J; Marks LS; Pearson JD; Rittenhouse HG; Chan DW; Shery ED; Gormley GJ; Subong EN; Kelley CA; Stoner E; Partin AW
J Urol; 1998 Feb; 159(2):449-53. PubMed ID: 9649261
[TBL] [Abstract][Full Text] [Related]
2. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Keetch DW; Andriole GL; Ratliff TL; Catalona WJ
Urology; 1997 Dec; 50(6):901-5. PubMed ID: 9426721
[TBL] [Abstract][Full Text] [Related]
3. The effect of finasteride on prostate specific antigen: review of available data.
Guess HA; Gormley GJ; Stoner E; Oesterling JE
J Urol; 1996 Jan; 155(1):3-9. PubMed ID: 7490873
[TBL] [Abstract][Full Text] [Related]
4. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1997 Jul; 50(1):13-8. PubMed ID: 9218012
[TBL] [Abstract][Full Text] [Related]
5. Effects of finasteride on prostate volume and prostate-specific antigen.
Chiu KY; Yong CR
J Chin Med Assoc; 2004 Nov; 67(11):571-4. PubMed ID: 15720071
[TBL] [Abstract][Full Text] [Related]
6. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Bruskewitz R; Girman CJ; Fowler J; Rigby OF; Sullivan M; Bracken RB; Fusilier HA; Kozlowski D; Kantor SD; Johnson EL; Wang DZ; Waldstreicher J
Urology; 1999 Oct; 54(4):670-8. PubMed ID: 10510926
[TBL] [Abstract][Full Text] [Related]
7. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359.
Brawer MK; Lin DW; Williford WO; Jones K; Lepor H
Prostate; 1999 Jun; 39(4):234-9. PubMed ID: 10344212
[TBL] [Abstract][Full Text] [Related]
8. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
[TBL] [Abstract][Full Text] [Related]
9. Changes in molecular forms of prostate-specific antigen during treatment with finasteride.
España F; Martínez M; Royo M; Estellés A; Alapont JM; Navarro S; Aznar J; Jiménez-Cruz JF
BJU Int; 2002 Nov; 90(7):672-7. PubMed ID: 12410745
[TBL] [Abstract][Full Text] [Related]
10. Effect of finasteride on prostate-specific antigen density.
Gormley GJ; Ng J; Cook T; Stoner E; Guess H; Walsh P
Urology; 1994 Jan; 43(1):53-8; discussion 58-9. PubMed ID: 7506854
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
12. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial.
Guess HA; Heyse JF; Gormley GJ; Stoner E; Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):627-36. PubMed ID: 7505970
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
[TBL] [Abstract][Full Text] [Related]
14. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.
Andriole GL; Guess HA; Epstein JI; Wise H; Kadmon D; Crawford ED; Hudson P; Jackson CL; Romas NA; Patterson L; Cook TJ; Waldstreicher J
Urology; 1998 Aug; 52(2):195-201; discussion 201-2. PubMed ID: 9697781
[TBL] [Abstract][Full Text] [Related]
15. The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia.
Guess HA; Heyse JF; Gormley GJ
Prostate; 1993; 22(1):31-7. PubMed ID: 7678930
[TBL] [Abstract][Full Text] [Related]
16. Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group.
Oesterling JE; Roy J; Agha A; Shown T; Krarup T; Johansen T; Lagerkvist M; Gormley G; Bach M; Waldstreicher J
Urology; 1998 Apr; 51(4A Suppl):58-63. PubMed ID: 9586598
[TBL] [Abstract][Full Text] [Related]
17. [Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer].
Morote J; Lorente JA; Raventós CX; López MA; Encabo G; De Torres I; López M; De Torres JA
Actas Urol Esp; 1998; 22(10):835-9. PubMed ID: 9949572
[TBL] [Abstract][Full Text] [Related]
18. Differential suppression of serum prostatic acid phosphatase and prostate-specific antigen by 5-alpha-reductase inhibitor.
Narayan P; Tewari A; Jacob G; Mahmood I; Gajendran V; Presti J
Br J Urol; 1995 May; 75(5):642-6. PubMed ID: 7542134
[TBL] [Abstract][Full Text] [Related]
19. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J
J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304
[TBL] [Abstract][Full Text] [Related]
20. Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia.
Matzkin H; Barak M; Braf Z
Br J Urol; 1996 Sep; 78(3):405-8. PubMed ID: 8881951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
